Taiwan Liposome Company (TLC) has dosed the first patients in a Phase I/II trial to investigate TLC590 in comparison with free, non-liposomal ropivacaine when given as a single infiltrative local administration for the treatment of adult patients following inguinal hernia repair surgery.

The randomised, double-blind, comparator-controlled, dose-escalation trial has so far included 12 patients, three of whom were dosed.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial aims to analyse the safety, tolerability, pharmacokinetics (PK), dose-exposure relationships, and analgesic efficacy of dose escalation of TLC590 compared to free, non-liposomal ropivacaine.

It is currently being carried out in the US with plans to enrol around 64 patients who will be followed up for 30 days after surgery and dosing.

“The randomised, double-blind, comparator-controlled, dose-escalation trial has so far included 12 patients, three of whom were dosed.”

Taiwan Liposome Company founder, chairman and CEO Dr Keelung Hong said: “TLC590 is formulated with our proprietary BioSeizer liposome technology, which has a dense multilamellar structure capable of providing high-concentration drug loading and continuous release of ropivacaine,.

“Our preclinical studies have shown TLC590 to display statistically significant analgesic efficacy compared to liposomal bupivacaine, and we are excited to have begun dosing patients in our first-in-human clinical trial to demonstrate TLC590 as a potentially best-in-class drug for postsurgical pain management that may serve as a safe, non-opioid solution to the opioid epidemic.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Ropivacaine, a common local anesthetic drug in the amino amide group that was developed after bupivacaine, was previously demonstrated to have less cardiovascular and central nervous system toxicity than bupivacaine.

Bupivacaine is currently being used in the US and has demonstrated significant efficacy up to 24 hours post-surgery, but showed minimal to no efficacy between 24 and 72 hours after administration.